BACKGROUND: The National Institutes of Health (NIH) consensus statement recommends adjuvant therapy for early breast cancer irrespective of age. However, the actual use of such therapy is not well documented among women over 65 years of age. METHODS: We studied the frequency of use of adjuvant therapy and report the receipt of this therapy among 200 women aged > or = 65 years diagnosed with early breast cancer who were identified from the New Jersey State Cancer Registry. RESULTS: In this population, 28% of patients received chemotherapy alone or in combination with hormonal therapy, whereas 42% received hormonal therapy alone. Less than half of the women with estrogen receptor-negative tumors received chemotherapy alone or in combination with hormonal treatment. Adjuvant therapy was not prescribed in 30% of patients. CONCLUSIONS: Despite NIH recommendations, the frequency of use of adjuvant therapy in New Jersey is low among women over 65 years of age, regardless of their receptor status.
BACKGROUND: The National Institutes of Health (NIH) consensus statement recommends adjuvant therapy for early breast cancer irrespective of age. However, the actual use of such therapy is not well documented among women over 65 years of age. METHODS: We studied the frequency of use of adjuvant therapy and report the receipt of this therapy among 200 women aged > or = 65 years diagnosed with early breast cancer who were identified from the New Jersey State Cancer Registry. RESULTS: In this population, 28% of patients received chemotherapy alone or in combination with hormonal therapy, whereas 42% received hormonal therapy alone. Less than half of the women with estrogen receptor-negative tumors received chemotherapy alone or in combination with hormonal treatment. Adjuvant therapy was not prescribed in 30% of patients. CONCLUSIONS: Despite NIH recommendations, the frequency of use of adjuvant therapy in New Jersey is low among women over 65 years of age, regardless of their receptor status.
Authors: Amy K Alderman; E Dale Collins; Anne Schott; Melissa E Hughes; Rebecca A Ottesen; Richard L Theriault; Yu-Ning Wong; Jane C Weeks; Joyce C Niland; Stephen B Edge Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Nicole Leoce; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Dawn L Hershman Journal: Breast Cancer Date: 2014-06-06 Impact factor: 4.239
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Nicole Leoce; S David Nathanson; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Carol Magai; Wei Yann Tsai; Judith S Jacobson; Dawn L Hershman Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Linda C Harlan; Carrie N Klabunde; Anita H Ambs; Todd Gibson; Leslie Bernstein; Anne McTiernan; Kathleen Meeske; Kathy B Baumgartner; Rachel Ballard-Barbash Journal: J Cancer Surviv Date: 2009-05-13 Impact factor: 4.442
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Donna L Buono; S David Nathanson; Dana H Bovbjerg; Jeanne S Mandelblatt; Wei-Yann Tsai; Judith S Jacobson; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2016-06-10 Impact factor: 4.872